Unusual Volume Buzz: EDAP TMS S.A. (ADR) (NASDAQ:EDAP), NeoGenomics (NASDAQ:NEO), Control4 Corp (NASDAQ:CTRL), Agile Therapeutics Inc (NASDAQ:AGRX)

Posted by on Jun 24, 2014

On June 3, 2014, EDAP TMS S.A. (ADR) (NASDAQ:EDAP) announced the closing on June 2, 2014 of a $9.3 million registered direct offering of ordinary shares in the form of American Depositary Shares (“ADSs”), at a price of $3.11 per share, with no warrants. The Company intends to use a portion of the net proceeds to advance preparatory activities in connection with the Ablatherm-HIFU PMA process and the upcoming U.S. Food and Drug Administration (FDA) Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee scheduled for July 30, 2014. The Company also intends to utilize the net proceeds to invest significantly in the expansion of its U.S. operations in preparation for the potential approval of its Ablatherm-HIFU. EDAP TMS S.A. (ADR) (NASDAQ:EDAP) net profit margin is -1.40% and weekly performance is 14.21%. On last trading day company shares ended up $4.42. Analysts mean target price for the company is $6.00. EDAP TMS S.A. (ADR) (NASDAQ:EDAP)distance from 50-day simple moving average (SMA50) is 31.33%.

NeoGenomics, Inc. (NASDAQ:NEO), announced that it was raising its previously issued revenue guidance for Quarter 2, 2014. The Company now expects revenue of approximately $20.0 – $20.5 million for the second quarter of 2014 compared with its previous estimate of $18.8 – $19.3 million. The Company also reaffirmed its previously issued earnings per share guidance of $0.00 – $0.01 for the quarter. NeoGenomics, Inc. (NASDAQ:NEO) shares advanced 9.90% in last trading session and ended the day on $3.33. NEO Gross Margin is 48.10% and its return on assets is 5.80%. NeoGenomics, Inc. (NASDAQ:NEO) quarterly performance is -7.24%.

Shares of Control4 Corp (NASDAQ:CTRL) have been given a consensus rating of “Buy” by the eight ratings firms that are covering the stock, American Banking and Market News reports. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $25.50. Control4 Corp (NASDAQ:CTRL) shares moved up 6.53% in last trading session and was closed at $19.26, while trading in range of $18.18 – $19.33. Control4 Corp (NASDAQ:CTRL) year to date (YTD) performance is 8.81%.

On June 20, 2014, Agile Therapeutics Inc (NASDAQ:AGRX) announced that patent U.S. 8,747,888 (‘888 Patent), was issued by the U.S. Patent and Trademark Office on June 10, 2014. The patent is a continuation of its prior patent US 8,246,978 and is intended to provide additional patent protection covering its contraceptive patch, Twirla™ ethinyl estradiol and levonorgestrel transdermal system. Agile Therapeutics Inc (NASDAQ:AGRX) ended the last trading day at $10.33. Company weekly volatility is calculated as 18.60% and price to cash ratio as 64.01. Agile Therapeutics Inc (NASDAQ:AGRX) showed a positive weekly performance of 52.36%.

Leave a Reply

Your email address will not be published. Required fields are marked *